Related Experiment Video
Updated: Feb 8, 2026

Measuring Endoreduplication by Flow Cytometry of Isolated Tuber Protoplasts
Published on: March 9, 2018
Calcification in cerebral parenchyma affects pharmacoresistant epilepsy in tuberous sclerosis
Meng-Na Zhang1, Li-Ping Zou2, Yang-Yang Wang1
1Department of Pediatrics, Chinese PLA General Hospital, Beijing, China.
Purpose:
Tuberous sclerosis (TSC) is an autosomal dominant inherited disease caused by mutations in the TSC1 or TSC2 gene and results in the over-activation of the mammalian target of the rapamycin (mTOR) signaling pathway. Rapamycin, an mTOR inhibitor, is clinically used to treat hamartomatous lesionsas in TSC and its effect on controlling epilepsy is also reported in many studies. This study aims to evaluate the risk factors of pharmacoresistant epilepsy in patients with TSC receiving long-term rapamycin treatment.
Method:
A total of 108 patients with TSC taking rapamycin for over 1 year were enrolled in this study. Factors that might influence seizure control were statistically analyzed by multiple factor analysis. A subgroup analysis was also conducted to access the relationship between calcified epileptic foci and pharmacoresistant epilepsy. (Clinical trial registration number: ChiCTR-OOB-15006535(2015-05-29)).
Results:
Seizure was controlled in 53 patients but was not managed in 55 patients considered to be drug resistant. Logistic regression analysis showed that calcification in the cerebral parenchyma was a risk factor of pharmacoresistant epilepsy [P = 0.006, odds ratio (OR) = 4.831 (1.577, 14.795)]. Fifteen of 17 patients with calcified epileptic foci suffered from pharmacoresistant epilepsy (88.2%). Seizures in patients with calcified epileptic foci were probably pharmacoresistant (P = 0.010).
Conclusion:
Calcification in epileptic foci strongly indicates pharmacoresistant epilepsy in patients with TSC even when treated with appropriate anti-epilepsy drugs (AEDs) and rapamycin. Calcification can be used to evaluate pharmacoresistant epilepsy in patients with TSC.
Insights
Calcification in epileptic foci is a strong indicator of pharmacoresistant epilepsy in Tuberous Sclerosis Complex (TSC) patients, even with rapamycin treatment. This finding aids in evaluating treatment resistance in TSC patients.
Area of Science:
- Neurology
- Genetics
- Pharmacology
Background:
- Tuberous Sclerosis Complex (TSC) is an autosomal dominant disorder caused by TSC1 or TSC2 gene mutations.
- It leads to overactivation of the mammalian target of rapamycin (mTOR) signaling pathway.
- Rapamycin, an mTOR inhibitor, is used for TSC hamartomatous lesions and shows promise for epilepsy control.
Purpose of the Study:
- To identify risk factors for pharmacoresistant epilepsy in TSC patients undergoing long-term rapamycin therapy.
- To evaluate the impact of calcified epileptic foci on treatment outcomes.
Main Methods:
- 108 TSC patients on rapamycin for over 1 year were analyzed.
- Multiple factor analysis was used to identify seizure control predictors.
- Subgroup analysis focused on the link between calcified foci and pharmacoresistant epilepsy.
Main Results:
- 55 out of 108 patients had drug-resistant epilepsy.
- Cerebral parenchymal calcification was a significant risk factor for pharmacoresistant epilepsy (OR=4.831, P=0.006).
- 88.2% of patients with calcified foci experienced pharmacoresistant epilepsy.
Conclusions:
- Calcification in epileptic foci strongly predicts pharmacoresistant epilepsy in TSC patients.
- This finding is relevant even with concurrent anti-epilepsy drugs and rapamycin.
- Calcification serves as a valuable marker for assessing pharmacoresistant epilepsy in TSC.
Related Concept Videos
Epilepsy and Seizures: Overview
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Cerebral Hemispheres
What is a Sensory System?
Hearing
Vision

